Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global gene therapy for mucopolysaccharidosis market was valued at USD 627 million in 2023 and is projected to reach USD 1.24 billion by 2030, exhibiting a CAGR of 9.8% during the forecast period. This growth trajectory reflects increasing clinical trial activity and expanding therapeutic approvals for these rare genetic disorders.
Gene therapy for mucopolysaccharidosis involves introducing functional copies of defective genes into patients' cells to correct the underlying enzyme deficiencies. These therapies primarily target lysosomal storage disorders caused by mutations in genes encoding enzymes that break down glycosaminoglycans. Recent advances in viral vector technology, particularly adeno-associated viruses (AAVs), have significantly improved treatment efficacy and safety profiles.
The market expansion is driven by several factors including rising orphan drug designations, favorable reimbursement policies for rare disease treatments, and increased research funding. The recent FDA approval of gene therapies for related lysosomal storage disorders has created a positive regulatory precedent. However, challenges remain in addressing blood-brain barrier penetration for neurological manifestations and managing high treatment costs that can exceed USD 1 million per patient. Key players like Sangamo Therapeutics and uniQure are advancing late-stage clinical programs, with several Phase III trials expected to read out in 2025-2026.
Increasing Prevalence of Mucopolysaccharidosis Disorders
The rising incidence of mucopolysaccharidosis (MPS) disorders, affecting approximately 1 in 25,000 births globally, is driving demand for gene therapy solutions. With limited treatment options currently available, gene therapy presents a potentially curative approach for these rare genetic conditions.
Advances in Gene Editing Technologies
Breakthroughs in CRISPR and other gene editing platforms have accelerated development of targeted therapies for MPS. The ability to precisely correct genetic mutations is particularly valuable for these monogenic disorders.
FDA's orphan drug designation for multiple MPS gene therapies is accelerating clinical development timelines
Growing investment in rare disease research, with venture funding for gene therapy startups increasing by 35% annually, is further propelling market growth.
MARKET CHALLENGES
High Development Costs and Complexity
Gene therapy development for ultra-rare diseases like MPS requires specialized expertise and substantial investment, with average costs exceeding $2 million per patient in clinical trials.
Other Challenges
Manufacturing Scalability
Producing viral vectors at commercial scale remains a significant bottleneck, particularly for diseases requiring CNS delivery.
Regulatory Hurdles
Unique safety assessments are required for integrating vector therapies targeting lifelong expression in MPS patients.
Limited Patient Population
With individual MPS subtypes affecting fewer than 1,000 patients worldwide, the addressable market for each therapy is constrained. This challenges traditional pharma business models requiring blockbuster revenues.
Novel Delivery Mechanisms
Innovations in blood-brain barrier penetration and tissue-specific targeting present opportunities to address MPS conditions affecting multiple organ systems. Recent progress in AAV capsid engineering shows particular promise for CNS manifestations.
Global Expansion
Emerging markets are establishing rare disease registries and specialty treatment centers, creating new access opportunities for advanced therapies in regions with previously undiagnosed MPS populations.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Intravenous therapy dominates due to its non-invasive administration and systemic treatment capabilities. ICV delivery shows promising potential for targeted central nervous system treatment of neurological symptoms in MPS disorders. |
| By Application |
|
Mucopolysaccharidosis II (Hunter syndrome) represents the most actively targeted application segment due to its severe manifestation and high unmet medical need. Research efforts are expanding rapidly for MPS III variants with neurological involvement, representing significant future growth potential. |
| By End User |
|
Specialty clinics are emerging as preferred treatment centers due to the complex nature of MPS disorders requiring multidisciplinary care. Research institutes play a crucial role as early adopters and developers of novel gene therapy approaches, with several academic medical centers conducting clinical trials. |
| By Disease Severity |
|
Severe MPS cases represent the primary target for gene therapy interventions due to rapid disease progression and poor outcomes with conventional treatments. However, there is growing interest in early intervention strategies for attenuated forms to prevent disease complications. |
| By Therapeutic Approach |
|
Gene replacement approaches currently lead the therapeutic segment, offering potential one-time treatments. Gene editing technologies show significant promise for durable correction but face more regulatory and technical challenges in clinical translation compared to established viral vector-based gene therapy methods. |
Innovative Biotech Firms Drive Advancements in MPS Gene Therapies
Sangamo Therapeutics and Swedish Orphan Biovitrum currently lead the gene therapy market for Mucopolysaccharidosis (MPS) through pioneering research and strategic partnerships. The market structure is characterized by specialized biotech firms collaborating with larger pharmaceutical companies to accelerate clinical development and commercialization of these rare disease therapies. These leaders have demonstrated significant therapeutic potential in addressing enzyme deficiencies through gene transfer technologies.
Several emerging biopharmaceutical companies like REGENXBIO and Abeona Therapeutics are developing novel AAV-based gene therapy approaches for different MPS subtypes. Niche players such as ArmaGen and JCR Pharmaceuticals focus on blood-brain barrier penetration technologies to treat neurological manifestations, while established firms like BioMarin Pharmaceutical leverage their enzyme replacement therapy expertise to develop next-generation gene therapies.
List of Key Gene Therapy for Mucopolysaccharidosis Companies ProfiledSwedish Orphan Biovitrum (Sobi)
Abeona Therapeutics
ArmaGen
BioMarin Pharmaceutical
Lysogene
Taysha Gene Therapies
Neurogene
Passage Bio
The global Gene Therapy for Mucopolysaccharidosis market was valued at million in 2024 and is projected to reach US$ million by 2031, growing at a significant CAGR during the forecast period. This growth is primarily driven by increasing research into rare genetic disorders and advancements in gene therapy technologies. The market is responding to the urgent need for treatments for over 40 identified Mucopolysaccharidosis disorders, which currently lack curative options.
Other TrendsExpanding Treatment Modalities
Gene therapy approaches for Mucopolysaccharidosis are diversifying, with administration methods including intravenous, ICV, intracerebral, and intracisternal delivery systems. Each method targets different manifestations of the disease, with intracerebral approaches showing particular promise for neurological symptoms prevalent in Mucopolysaccharidosis III variants. Clinical trials are actively evaluating these different routes of administration to optimize therapeutic outcomes.
Regional Market DevelopmentsNorth America currently leads the market due to established regulatory pathways and significant biotech investment, followed by Europe where companies like Swedish Orphan Biovitrum are active. The Asia-Pacific region is emerging as a growth area, with increasing government support for rare disease research and improving healthcare infrastructure facilitating market expansion. South America and Middle East markets remain comparatively underdeveloped but show potential for gradual adoption.
Competitive Landscape Evolution
Key players such as Sangamo Therapeutics and uniQure are driving innovation through strategic partnerships and clinical trial advancements. The competitive landscape is characterized by a mix of established pharmaceutical companies and specialized biotech firms focusing on rare diseases. Market consolidation through mergers and acquisitions is expected as larger pharmaceutical companies seek to acquire promising gene therapy platforms for lysosomal storage disorders.
Regional Analysis: Gene Therapy for Mucopolysaccharidosis MarketEurope
Europe represents the second-largest market for MPS gene therapies, driven by coordinated rare disease networks and cross-border research collaborations. The EMA has implemented adaptive pathways for advanced therapy medicinal products, with several MPS therapies under evaluation. Countries like Germany and the UK lead in adoption, while Eastern European nations face slower uptake due to budget constraints. The region benefits from centralized treatment registries that enhance post-market surveillance of gene therapies. EU-funded research consortia are actively working on improving vector design and delivery methods specific to MPS disorders.
Asia-Pacific
The Asia-Pacific region shows the fastest growth potential for MPS gene therapies, particularly in developed markets like Japan and Australia. Japan's SAKIGAKE designation provides accelerated approval for innovative treatments, including gene therapies for rare diseases. China is investing heavily in gene editing technologies, though MPS-specific applications remain in early stages. The region faces challenges in disease awareness and diagnosis rates, which currently limit market size. However, increasing healthcare investments and growing biotechnology capabilities suggest significant future potential.
South America
South America's MPS gene therapy market remains in nascent stages, concentrated primarily in Brazil and Argentina. Academic medical centers are beginning to participate in international clinical trials, though local manufacturing capabilities are limited. High treatment costs relative to GDP per capita create significant access barriers. Some countries have established rare disease policies that may eventually facilitate gene therapy access, but implementation timelines remain uncertain. Patient organizations are actively advocating for improved treatment options.
Middle East & Africa
This region has minimal current participation in MPS gene therapy development, though specialized centers in Saudi Arabia and South Africa show growing interest. High prevalence of consanguinity increases MPS incidence rates in some populations, creating unmet medical need. Most patients currently rely on enzyme replacement therapy due to gene therapy cost barriers. International collaborations and humanitarian programs represent potential avenues for future access, though infrastructure limitations remain significant obstacles.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global gene therapy for mucopolysaccharidosis market was valued at USD 627 million in 2023 and is projected to reach USD 1.24 billion by 2030.
-> The market is exhibiting a CAGR of 9.8% during the forecast period.
-> Key players include Sangamo Therapeutics, Swedish Orphan Biovitrum, and uniQure.
-> Major types include Intravenous, ICV, Intracerebral, and Intracisternal gene therapies.
-> Key applications target Mucopolysaccharidosis I, II, III A, and III B subtypes.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates